Diagnostic Value of Next-Generation Sequencing Analysis in Biliary Tract Tumours
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Dec 10, 2024
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving the diagnosis of biliary tract tumors, which are growths that can occur in the bile ducts. Researchers are working to develop a special test called next-generation sequencing (NGS) that can help identify specific types of changes in the DNA of these tumors. By using this advanced testing alongside traditional methods like examining tissue samples under a microscope, the goal is to make it easier and more accurate to diagnose conditions such as dysplasia (abnormal cell growth) and cholangiocarcinoma (a type of cancer).
If you're at least 18 years old and have enough tissue available for testing, you might be eligible to participate in this study. There are no specific exclusions, meaning many people with the right tissue samples could join. Participants can expect to provide a tissue sample that will be analyzed using the new NGS technology. This research could lead to better diagnostic tools for patients with biliary tract issues, potentially improving treatment options and outcomes in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Availability of enough tissue for histological and NGS analysis (at least 20 ng DNA).
- • Age greater than/equal to 18 years.
- Exclusion Criteria:
- • None
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Francesco Vasuri, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported